 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Agios
AGIO
conference date: October 31, 2024, @ 5:00 AM Pacific Time
Agios Pharmaceuticals A Buy On Coming Revenue Ramp [July 26, 2022 at Seeking Alpha]
Agios Pharmaceuticals A Buy For Tibsovo, Mitapivat [September 1, 2020 at Seeking Alpha]
Agios: A Targeted Pharmaceutical Stairway To Value [January 13, 2020 at Seeking Alpha]
Agios A Buy On Stock Price Retreat, Cholangiocarcinoma Results [June 19, 2019 at Seeking Alpha]
Questioning Agios Pharmaceuticals' Future Revenue [December 7, 2018 at Seeking Alpha]
| 2024 | |||
| Agios Q4 2023 results |
Agios Q1 2024 results |
Agios Q2 2024 results |
Agios Q3 2024 results |
| Feb. 15, 2024 | May 2, 2024 | Aug. 1, 2024 | Oct. 31, 2024 |
| 2023 | |||
| Agios Q4 2022 results |
Agios Q1 2023 results |
Agios Q2 2023 results |
Agios Q3 2023 results |
| Feb. 23, 2023 | May 4, 2023 | Aug. 3, 2023 | Nov. 2, 2023 |
| 2022 | |||
| Agios Q4 2021 results |
Agios Q1 2022 results |
Agios Q2 2022 results |
Agios Q3 2022 results |
| Feb. 24, 2022 | May 5, 2022 | Aug. 4, 2022 | Nov. 3, 2022 |
| 2021 | |||
| Agios Q4 2020 results |
Agios Q1 2021 results |
Agios Q2 2021 results |
Agios Q3 2021 results |
| Feb. 25, 2021 | April 29, 2021 | July 29, 2021 | Nov. 3, 2021 |
| 2020 | |||
| Agios Q4 2019 results |
Agios Q1 2020 results |
Agios Q2 2020 results |
Agios Q3 2020 results |
| Feb. 13, 2020 | April 30, 2020 | July 30, 2020 | Nov. 5, 2020 |
| 2019 | |||
| Agios Q4 2018 results |
Agios Q1 2019 results |
Agios Q2 2019 results |
Agios Q3 2019 results |
| Feb. 14, 2019 | May 2, 2019 | August 1, 2019 | Oct. 31, 2019 |
2018 |
|||
Feb. 14, 2018 |
May 4, 2018 |
August 2, 2018 |
Nov. 1, 2018 |
2017 |
|||
02/16/2017 |
May 4, 2017 |
August 8, 2017 |
Nov. 1, 2017 |
2016 |
|||
02/18/16 |
05/05/2015 |
08/04/2016 |
11/03/2016 |
Buy Agios [January 10, 2018 at Seeking Alpha]
AML Therapies, Part 2: Agios and Immunogen [September 29, 2016 at Seeking Alpha]
Agios (AGIO) is a commercial stage biotechnology company specializing in rare disease therapies. It sold its first commercial therapy. Its second is Pyrukynd for PK deficiency.
More Analyst Conference Pages:
| AGEN |
| ALNY |
| ALXN |
| ALNY |
| ALLO |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| IONS |
| INCY |
| INO |
| MCHP |
| MRNA |
| REGN |
| RNA |
| SAGE |
| SANA | SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2024 William P. Meyers